0001104659-23-098499.txt : 20230906 0001104659-23-098499.hdr.sgml : 20230906 20230906070806 ACCESSION NUMBER: 0001104659-23-098499 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230901 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20230906 DATE AS OF CHANGE: 20230906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 231237840 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 8-K 1 tm2325490d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2023

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38129

04-3562403

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

840 Memorial Drive Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 498-0020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	MRSN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Anna Protopapas

On September 1, 2023, Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, Inc. (the “Company”), provided the Company with notice of her desire and intention to retire, and on September 6, 2023, the Company announced Ms. Protopapas’ retirement effective as of September 10, 2023 (the “Retirement Date”). Ms. Protopapas will remain a member of the Company’s Board of Directors

In connection with Ms. Protopapas’ retirement, on September 5, 2023, the Company entered into a retirement and separation agreement (the “Retirement Agreement”) with Ms. Protopapas. Pursuant to the Retirement Agreement, the Company agreed that it will pay Ms. Protopapas the annual cash bonus under the Company’s 2017 Cash Bonus Plan to which Ms. Protopapas would have been entitled for the fiscal year ending December 31, 2023 had she remained employed by the Company through such date, pro-rated for the portion of 2023 for which Ms. Protopapas was actually employed by the Company (the “2023 Bonus”), such 2023 Bonus to be based on Company performance as assessed by the Company’s Board of Directors or a duly authorized committee thereof following December 31, 2023. The 2023 Bonus will be payable at the time the Company pays management bonuses for 2023, but in no event later than March 15, 2024. In addition, pursuant to the Retirement Agreement, (i) the stock option granted to Ms. Protopapas on January 15, 2021 (the “2021 Option”) will cease vesting on the Retirement Date, following which date Ms. Protopapas will have a period of three months to exercise the vested portion of the 2021 Option, (ii) the Company agreed to extend the vesting of Ms. Protopapas’ outstanding stock options and restricted stock unit (“RSU”) awards, other than the 2021 Option, through January 31, 2025, subject to Ms. Protopapas’ continued service to the Company as a director through such date and (iii) other than with respect to the 2021 Option, the exercise period for each stock option held by Ms. Protopapas will expire upon the earlier of the end of the applicable term of the option and three months after Ms. Protopapas ceases to be a member of the Company’s Board of Directors.

The Retirement Agreement also includes a general release of claims by Ms. Protopapas.

After her retirement, Ms. Protopapas will receive compensation for her continued service as a member of the Company’s Board of Directors in accordance with the Company’s current non-employee director compensation policy. The Company agreed to grant, effective as of September 11, 2023, Ms. Protopapas an equity award in the form of (i) an option to purchase 16,643 shares of the Company’s common stock, which option will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the date of grant and (ii) a RSU award for 16,643 shares of the Company’s common stock, each of which will vest in full on the earlier to occur of June 8, 2024 or the date of the Company’s 2024 annual meeting of stockholders, subject to Ms. Protopapas’ continuous service to the Company on such vesting date. Such equity award will be granted pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”) and was calculated based on the terms of the annual equity grant for which non-employee directors are eligible under the Company’s non-employee director compensation policy, pro-rated for the portion of the year for which Ms. Protopapas will serve as a non-employee director following the Company’s annual meeting of stockholders held in 2023.

Appointment of Martin Huber, M.D., as President and Chief Executive Officer

On September 6, 2023, the Company also announced that Martin Huber, M.D., was appointed as the Company’s President and Chief Executive Officer, effective as of September 11, 2023 (the “Huber Start Date”). Dr. Huber will continue to serve on the Company’s Board of Directors.

Dr. Huber, age 63, has served as a member of the Company’s Board of Directors since April 2020 and joins the Company from Xilio Therapeutics, Inc., a biotechnology company, where he most recently served as President, Head of R&D since June 2022, and, prior to that, served as President of R&D from August 2021 to June 2022 and as Chief Medical Officer from April 2020 to June 2022. Before joining Xilio, Dr. Huber served as Chief Medical Officer at TESARO, Inc. (“TESARO”), an oncology-focused company, from September 2015 until TESARO’s acquisition by GlaxoSmithKline plc in January 2019, and therafter as Senior Vice President, Clinical, from January 2019 to April 2020. Dr. Huber has served on the board of directors of Syndax Pharmaceuticals, Inc., a biotechnology company, since September 2021. Dr. Huber received his B.S. in biology from Texas Lutheran College and his M.D. from Baylor College of Medicine.

In connection with Dr. Huber’s appointment as the Company’s President and Chief Executive Officer, on September 5, 2023, the Company entered into an employment offer letter with Dr. Huber (the “Offer Letter”). The Offer Letter entitles Dr. Huber to an initial base salary of $625,000 per year and makes him eligible to receive an annual discretionary performance bonus targeted at 60% of his annual base salary, subject to the achievement of performance goals determined by the Company’s Board of Directors. The amount, terms and conditions of any annual bonus will be determined by the Company’s Board of Directors in its discretion, subject to the terms and conditions of any applicable bonus plan in effect from time to time. Any bonus paid to Dr. Huber for 2023 will be prorated to the Huber Start Date.

Pursuant to the Offer Letter, Dr. Huber will receive an option to purchase 1,000,000 shares of the Company’s common stock, which will be issued pursuant to the Plan. The option will vest as to 25% of the shares subject to the option on the first anniversary of the Huber Start Date and as to 6.25% of the shares subject to the option on the last date of each three-month period thereafter, subject to Dr. Huber’s employment through each applicable vesting date. The options will have an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Market on the date of grant. In addition, pursuant to the Offer Letter, Dr. Huber will receive a RSU award for 667,000 shares of the Company’s common stock, which shall be issued pursuant to the Plan. The RSU award will vest as to 25% of the shares on each of the first four anniversaries of the Huber Start Date, subject to Dr. Huber’s continued employment through each applicable vesting date.

Under the terms of the Offer Letter, in the event Dr. Huber’s employment with the Company is terminated other than for disqualifying conduct (as defined in the Offer Letter) or Dr. Huber resigns for good reason (as defined in the Offer Letter), Dr. Huber will be eligible to receive, for twelve months following the date of termination, (i) his base salary as in effect on the date of termination (or, to the extent his base salary was reduced giving rise to good reason, as in effect immediately prior to such reduction), and (ii) provided that he timely elects to continue coverage in the Company’s group health plans in accordance with COBRA or applicable state law, a portion of the COBRA or applicable state law premium contributions equal to the excess of the cost of such premiums for himself, his spouse and dependents over the amount that he would have paid for such coverage had he remained continuously employed by the Company.

In the event Dr. Huber is terminated other than for disqualifying conduct or Dr. Huber resigns for good reason, in each case, on or within 12 months following the consummation of a change in control (as defined in the Offer Letter) of the Company, in lieu of the payments described above, Dr. Huber will be eligible to receive (i) a lump sum cash severance payment equal to the sum of (A) eighteen months of his base salary and (B) 1.5 (one and one-half) times his annual target bonus, in each case as in effect on the date of termination, and (ii) for a period of eighteen months following termination, provided that he timely elects to continue coverage in the Company’s group health plans in accordance with COBRA or applicable state law, a portion of the COBRA or applicable state law premium contributions equal to the excess of the cost of such premiums for himself, his spouse and dependents over the amount that he would have paid for such coverage had he remained continuously employed by the Company. Additionally, Dr. Huber’s stock options and other equity-based awards to the extent outstanding immediately prior to his termination, will be treated as having vested in full as of immediately prior to his termination.

Dr. Huber’s entitlement to each payment described in the foregoing two paragraphs is conditioned on his execution of a release of claims in favor of the Company and his continued compliance with a confidentiality agreement.

Additionally, the terms of the existing indemnification agreement between Dr. Huber and the Company will remain in effect, providing indemnification protection for Dr. Huber in connection with his service as an executive officer. A copy of the Company’s form of indemnification agreement was filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 16, 2017 and is incorporated herein by reference. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Dr. Huber for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as the Company’s President and Chief Executive Officer.

There is no arrangement or understanding between Dr. Huber and any other person pursuant to which Dr. Huber was selected as the Company’s President and Chief Executive Officer. There are no related party transactions between the Company and Dr. Huber reportable under Item 404(a) of Regulation S-K and no family relationships between Dr. Huber and any of the Company’s directors or officers.

The foregoing descriptions of the Retirement Agreement and the Offer Letter are summaries only and are qualified by reference in their entirety to the Retirement Agreement and the Offer Letter, copies of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

Arvin Yang Separation Agreement

On September 6, 2023, the Company also announced that the Company and Arvin Yang, M.D., Ph.D., the Company’s Senior Vice President, Chief Medical Officer, have agreed that Dr. Yang’s last day with the Company will be September 29, 2023. The Company anticipates that it will enter into a separation agreement (the “Separation Agreement”) with Dr. Yang, pursuant to which Separation Agreement the Company will (i) pay to Dr. Yang severance in an amount equivalent to nine months of Dr. Yang’s current base salary, subject to customary payroll withholding and other deductions; and (ii) if Dr. Yang elects continued group health insurance coverage under COBRA, pay, until the earlier of (x) nine months following his separation and (y) the date on which Dr. Yang obtains alternative coverage, the share of the premiums for such coverage to the same extent the Company was paying such premiums on his behalf immediately prior to his separation.

The Separation Agreement will also include a general release of claims by Dr. Yang.

The foregoing description of the Separation Agreement is a summary only and is qualified by reference in its entirety to the Separation Agreement, a copy of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

Appointment of Brian DeSchuytner as Chief Operating Officer

On September 6, 2023, the Company announced the appointment of Brian DeSchuytner as the Company’s Senior Vice President, Chief Operating Officer and Chief Financial Officer. Mr. DeSchuytner will continue to serve as the Company’s principal financial officer.

Mr. DeSchuytner, age 45, has served as the Company’s Senior Vice President, Chief Financial Officer since October 2021 and, prior to that, served as the Company’s Senior Vice President, Finance and Product Strategy, from June 2019 until October 2021. Prior to joining the Company, Mr. DeSchuytner served as Vice President, ZEJULA Commercial, at TESARO from January 2017 to June 2019. Mr. DeSchuytner received his B.A. in biophysical chemistry from Dartmouth College and his M.B.A., concentrating in finance and health care management, from the Wharton School of the University of Pennsylvania.

There is no arrangement or understanding between Mr. DeSchuytner and any other person pursuant to which Mr. DeSchuytner was selected as the Company’s Senior Vice President, Chief Operating Officer and Chief Financial Officer. There are no related party transactions between the Company and Mr. DeSchuytner reportable under Item 404(a) of Regulation S-K and no family relationships between Mr. DeSchuytner and any of the Company’s directors or officers.

Item 8.01

Other Events

Officer Appointments

On September 6, 2023, the Company also announced the appointment of Mohan Bala, Ph.D., as the Company’s Senior Vice President, Chief Development Officer. Prior to his appointment, Dr. Bala served as the Company’s Senior Vice President, Strategic Product Planning and Program Leadership.

On September 6, 2023, the Company announced the appointment of Ashish Mandelia as the Company’s Vice President, Chief Accounting Officer. Prior to his appointment, Mr. Mandelia served as the Company’s Vice President, Controller. Mr. Mandelia will continue to serve as the Company’s principal accounting officer.

Other Compensatory Arrangements

On September 5, 2023, the Compensation Committee of the Board granted an aggregate of 330,000 RSUs as retention awards to members of its senior management team. The RSUs will vest in full on October 1, 2024, subject to each grantee’s continued employment by the Company on such date.

Board Committee Reconstitutions

In connection with Dr. Huber’s appointment as the Company’s President and Chief Executive Officer, Dr. Huber has stepped down from his positions on the Compensation Committee and the Nominating and Corporate Governance Committee of the Company’s Board of Directors, effective as of September 11, 2023. As of October 1, 2023, the Compensation Committee and the Nominating and Corporate Governance Committee will be reconstituted as follows:

Compensation Committee	Nominating and Corporate Governance Committee
David Mott (Chair)	Willard H. Dere (Chair)
Allen Diaz	Lawrence Alleva
Kristen M. Hege, M.D.	Kristen M. Hege

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERSANA THERAPEUTICS, INC.

Date: September 6, 2023	By:	/s/ Brian DeSchuytner
		Senior Vice President, Chief Operating Officer and Chief Financial Officer

EX-101.SCH 2 mrsn-20230901.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 mrsn-20230901_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 mrsn-20230901_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 01, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 01, 2023
Entity File Number	001-38129
Entity Registrant Name	MERSANA THERAPEUTICS, INC.
Entity Central Index Key	0001442836
Entity Tax Identification Number	04-3562403
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	840 Memorial Drive
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	617
Local Phone Number	498-0020
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	MRSN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 tm2325490d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001442836 2023-09-01 2023-09-01 iso4217:USD shares iso4217:USD shares 0001442836 false 8-K 2023-09-01 MERSANA THERAPEUTICS, INC. DE 001-38129 04-3562403 840 Memorial Drive Cambridge MA 02139 617 498-0020 false false false false Common Stock, $0.0001 par value MRSN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mersana.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2325490d1_8k.htm mrsn-20230901.xsd mrsn-20230901_lab.xml mrsn-20230901_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2325490d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2325490d1_8k.htm" ] }, "labelLink": { "local": [ "mrsn-20230901_lab.xml" ] }, "presentationLink": { "local": [ "mrsn-20230901_pre.xml" ] }, "schema": { "local": [ "mrsn-20230901.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrsn", "nsuri": "http://mersana.com/20230901", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325490d1_8k.htm", "contextRef": "AsOf2023-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mersana.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2325490d1_8k.htm", "contextRef": "AsOf2023-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-098499-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-098499-xbrl.zip M4$L#!!0 ( (Y)E=E?>+B*0, . + 1 ;7)S;BTR,#(S,#DP,2YX M],_T'U:\>6#4T:""23DJ9#AS09:"[-2T?8@JBQ)5>2N?3K M*]F6N1A]NS*M\UD4@@GF@C#:MCS'M0"F/@L(';>MNX%],>AT MNQ8X/WO]"JA?ZXUM@RN"PZ )+IEO=^F(G8(O*,)-\ E3S)%D_!3-W_6ZA^RQE+)H03J=3A[()FC+^ M(AR?1;L)#B22B2C4W)F;_W:C7Q/A%^2WZ.)H^G[6)X]C3$^2'JH_^0_HX7-G M>!/\>NJ_G7][F#C]>]08JS,F!S%A+ZL@GN-1H-F'H-M(2<#7EHI.M0 MNX=(X$)9>4D%GE A$?57\($L",O@(Y@Y5Z!D(_0X@Q(##? :3F#?&;,)5 Z% MK]4-,!'V&*&X (^0&*:BN6,%++@L Y5Q'63+>8S%1FCF6B%$7- "&ZDQ1Q3I MD4Q!;L/UU&*%.,)47C$>7>(12D*5Q\\$A61$<& !B?@82SUC(D8^KA8SI>>88Z'H:44]9ZJ7XF*2^CC_]N-M0]$)$FG!V M/IH>?1PAPB(>)VQ]/OJZ&%\L9O/Y"*499C&FG)'S$>.C'W_X\Y^0_//IN_$8 M726$QF?H"X_&<_; OT$/.T$^$$8$S+KY'WS#=JBW\*J%$H!G?/%.2$5E0 M[/@,_?UH>AJA\7A O=\(B[GX>C^OZGW,LN?T;#)Y?7T]8OP%OW+QE!Y%?#.L MPD6&LVU:U?9Q]['\4X1_H@E[.E-_K7!*D#Q>+#W;I4-[,LVS_+%%*$T7"J-SV*,B#W0P58J+B)XRL<49BM:-3M:/I/]2._E)N MOL8K0D=(*24?8+M.&W6501/79N^(2'A\R=[GVHSV9%]^=T3V/S2@'N^\"4N> M8?HN\_5(Y[9OR/N.^"'._9&6XSQYWY&N1?Y?;&=MRV\^O/;C2M7&:_FI89'L M,CF!D5B;5%5TC,#Y'O*)H:R[JIU'C7JI&LVY:+==S8QYG2F)CM;\91*31-9] M?*(^C-6'O-GR/W_,N%P)7*S23. HTS7ES3@?6J7N%CI* MI:,-E0JUI")L_'4Q^B'7H-^UZC^?)H=:''2T7 )M-X1E2UFCI07-8E?=;#.E M>[E>%D0G6PR9?:PE2&D<=_"%W'&L=GY%\=IBWRAWU<566[J/&X5!=++-D=G+ ME08ID:]N_D+22"3/:CG?U8Z&S'FG6TRV^KZF"0N!MC&8A)K6T\!^3]:)FEJ4 M!75^2]3&CF$,T+L>^CMMFW.!51P$-$,<@K-%/0A549XXNF!LB^D]>>:B"Y^F MS#4U-I,F+'5-4(Q8C(%H%%I4B#T1\>M6GK$30?>]4+24KKD K)IH&+*@Z+![ M P&IY'X960K,TD0-8+V0M*7.3S< LZU3#T,7%"> .?B4I-+[)67Q2"A5]P,P MZQ]0;&+7M,"&35[:RJ"( >V!S.01J P)!YO+%[4ZE\ND@8VMZ7W"T[+=Q4\E M#A8AT^% BO(PI.(\D52[#='#4$OIFA[ JLF-(0N*&+LWD)5"CG*]?T@N63P( MD4KG!Q##IAV/4A0@'$UG?6A(M4\PKI(TPK3PNEY?9> 9>HA1K YILPM 7:330J:FH!(L!H# M:#AH\V=*O1 QDR.3P'3.8K+[F>S!=K5T;ID ;#:A,$0!46%W!F!1BE&N1E+N M!8P[D6RPV"^2J&>J: O=H@$9;;)AJ@*" [ &T%&JT6(^\SF3+/%N'DM0DX>D M>!Z\AQ)0[Q:6'MM-9@!Q0.AT.P0(DD&H&>43I#F+N'CFM<<=9GPK!\#]C,?P M"J4GRBU4@YK01*LS)"# AO@$,&N$?BB>24%35X!4#5Z(NXAC>:#2\I_K MA)$IV'ZKUBU='7:;3%F$ 9$$NP/X*94?] >D8M M"P6:XS^(?F9"@T)T%#<_(N:&3'>QUK9O+CK5CR5]O#V:#2 M"S)MJU9@#K+P<&EYZX-%!:CUC KQB4F^L+H5=X*_)"R"E\R0W LP@&DK-88V M/'3L!OOXJ1;$.L[K6%,LRGN_)%KF9Y1IFK0/,84F/$B:QGH'ET+M$XD[GF:8 M_CMY[CP1MXN]X&$U;(6DH0P/%9N]/F"*&"2#?)Q8E[BJ&QK65\F,O %ML M'5X!KA4& 8'-4?L5X.+J22%RWULC"ZN&VHUO?(&?R 0%OBJJAPP9?9Z+D.YSM/5>)5A(K4/ MW[4R9S.[::>:R'5!$+UKNFE-T[K<<6_^)I),[GG&-YLM*^_RV)X;!'2N>KG3 MINYQJRB(WN]R9I)0:E%3[!B+!:=)E&0)6_\B3SY%@FVMLHE< 0$;U#2T%4&@ M -HR.3@(D58ZAN!.$ 4AD1V1OP2H$@N)VX<'ZVS?)78%1;]A#0>L# *27GLF M+#)@'-4B4!&"\AB_V,S3=$O$F^"QA'A""#0/@-32AX@39+(7JB+0)UL+$FWE M_+B?'J^6249M)Y=MB;,Y"3!7S4A&>1!L *9,%O(RQ!_0]/BOJ[\A'>6X^V_X M4F"5/':QWZPX!;)/656N(.BPJ#FP2() ?9ETG##42E%A=9'=JJ&64MSC')7 M %AMZ:YO% ;1Z39'K2]_HZ\]#?F7N^A1FB+ "PEVF>NAWV;2'/[KFB 0Z##6 M.BDII4AK?;R0<)BRUOV+@+6W1<"Z9Q&P#G$1L!ZZ"%A[6P3HW18I0N2X=+NB MR1H#R0D[U:ZAZ+!L\F&1!H4*[ \<,ZH0=(AQG=$R3W&FTO.+3;[_*_G!TDI MYRRG99?-*JFE310$(UW.6FDMBZ1S-3%2:M=<;.,D(W%AYBIAF$4)IE5Z1-L5 M\?X09[0,-%^!TZ,/@Z%A)ELX%6$ZEV$5>$AUZ?I2>O$ QF^$TI\9?V4+@E/. M2%Q<2['=*>K6NWUBIL=V\Z$90!P$3D,< H_.J*#QDXI".JR\$N:%I&^<;EF& M1?XNN;"-3(#.+3F S28QAB@@4NS. $(J,2K4?E[0+K)'5(NLXG>'P 9"O M:W>:-M[:MFH#8J;3(/0.=YGSX[ V+J(\O6*9$?5[$<=3XH;*?>*8EL5V[IA* M$A >-E\=&60$TEHO+"PVF-+/VS1A)(4G(D/EE@6KQ28+#4E +-A\ 2SD4J2U M7EBXW!"QEM/;3X*_9H]E?E:P;8#:+1N=EIN,6*4!L=+E#V!&AZ B1J?4]0// M[I!0O,BR"+?4(G6,#6C68*:E"PD8R%R+%DHB=;WEAF=HR='7E*#LD:#+\F?H MZIG@BWI\_=)(%*D7(HI5.8NQL"'4)7;^JR.@X=9OC[2408#4:P_^'9(J ND0 MQ]3<2H9%_3PN-S'/R 9\VZ$_Q!5!0\UKCOKT0= TT*3)5![6/+G. Y&*])G- MJ)[<'E[B-42.5\86@\;"N*8(@A'0%K0LKO]6@)_<>=L53:(KRC%\E:6A<9PQ MKVW/2)9W$ 1$0-L5E"(O%Z)3+7&Q@$A&]U"YWJI:A> 5JI M9\3**M#OJA*4UV+[_?+ZIFOY26[6F^1?*YP2N>6_4$L#!!0 ( (Y)E>D M1+"?5 < --7 5 ;7)S;BTR,#(S,#DP,5]P&ULS9Q-<]LV$(;O MG>E_8-6S+,MNVEJQF[$5*Z.)$[N6DK2]9" 2DC & 0T 6M*_+T"*BCX(<'WA MV@=;IA; OL^"()< >/ENE?+HF2K-I+AJ=4].6Q$5L4R8F%VUOHS:UZ/^<-B* MM"$B(5P*>M42LO7NKY]_BNS/Y2_M=C1@E">]Z+V,VT,QE6^CSR2EO>@#%501 M(]7;Z"OAF3LB!XQ3%?5ENN#44/M%T7 O>G/2O8BC=AM0[UA>I[-<+D^$?"9+J9[T22Q36(4C0TRFM[6=KDXW/T7Q2\[$4\_]FA!-(\M+ MZ-Y*LZN6:W?3[/+\1*I9Y^STM-OYY]/=*)[3E+29<-QBVBI+N5JJRG4O+BXZ M^;>EZ9'E:J)XV<9YIW1G6[/]E@7L=SS1K*=S]^YD3$P>]MIF(J^%^Z]=FK7= MH7;WK'W>/5GII%7"SPDJR>DCG4;NKXW>MM74]@$BB(M7QWW7Z4O;'ZVC>:FY MHM.K5JJTL)6?G9]>G.95_[IG9-8+VR\U<]VJ%77VFETHJJDPN=([>V"O"%T9 MVYMH4E;DV@.3F7SN))1UG'KW(<>0([#_?,\;NIYHHTALRIHXF5">U__=VAR8=!KPJB0Q MMC56.[5O<>C3;LRN51Q)E5!E69=U$17O1>JX6VXL.@NB;$7M>,[X-LA3)5,? MG0T)Z7%T%Y1MHAF:U[;]Q/DPX&16C?/ !,BSBP&T4@T6T?=4QXHM')<:L'N6 M0+YGJ'PKM#6,N3QW'NF,.7^=*^YB2]W!\+C@*0($?XXY4@35(D7@6HB,\$>Z MD*H&_+XED/=OF+RKM"%A_CLCRE#%UQ#21\9 V&\P87L4(O$>*R(T-8ULH;)3,,BP0A?:8K(:)5<6FK)@*K(?N+0)ECY)6@N2BA& H8JD6;@.2*\ 1D MOA+L9R_#?@;'CI*'ULI\)=C/7X;]'(X=)1>ME8F)O6\_WJNQ7'IFH+W&4.0H MN6B-1$S@^97F7CTH^+OOOL64* H"6B5F(9YWDDW]S&7(O@\]M@*RA4ED_2):GK@=>N(M??4W_D: MO((-95@]E-$PQF^*&>M!7Z9I)C;/:#RS8AY3*%Z4]"\HKV'4(\E9S P3LT_V M#E$QPJLY5]E!(:,D>WYA#1-^4-1%FMK;[GP=E]MHH.ZG4]_(&[*'$D?)]>J% MXI(?:IU1]5+^%:6@44!)^Z"BFQYG:)S986_=/9N,W8X9SRAS9 5EC9+R^40U MS/:S'"OB=NJ-UNE$WY4XSTP@8)%R>PJY2"-";>K M>$[$C/I7+U1;0@&C9'HA<6AC[PPT]LY>./:B9'P^44ALB[7A]HRZGW V(_Z= M9,$"X'TVF,0#4IO>OY=O^7%[N%6:^S&P'ZJQ>TRAP'&V2(;D-8TZ2YBA2>'2 M@ DB8IM2;?>U>;+S^E+0 .#LH02*1GF\_XUR_E'(I1A1HJ6@27&K'WK"[RT" MC0+B'&*-7)00?)4\LY14OA!4>+SMK+8E'S]MI3O*PC1-Q7 M @H><1(Q+!9I?9JASF?V3-\30S8>AOC[2D#Y(TXHAL6BK9]7?7OAF&-F\++7JH+P6- DJZ"A6-%^^9P;EBYB%5LA"P7M#Q)/*%B9>/R@9 M4^JF3_3V; ,D1, *H"%!S$]?A +G<8%,4[>92,9/H[D5K>\SD[^[U/H7?&@0 M+ <-#>8F3H!PI+L@_6.C%TUNUH]T2I5;IC"F*W-C&WH*WQ0!BD/C@_I&(3"& MBC!==HYTW=D#[NVTQ3?NEWL#JSWR/U!+ P04 " ".297-^(T:R\D "S MS0 $@ '1M,C,R-30Y,&0Q7SAK+FAT;>T]^5?;2-*_^SW_#_UY=_;!6]\< MX4C89\ A)%S!,#.97_+:4MM6D"5'DL'.7_]55;>DUF&#'9(P SL[ TA]5%?7 M7=6MU_^;#&UV*SS?05 MR_$#[A@BZF1;SLWL\?%MU+3KV5:B*3X))UFK98:&MV;<06^\69,O$TV#W*8; MLFD0-K5\=[W9>#4/#MDBZC"9U;:!,,,*Q9_[ER=Q\R"_?=RT%GC<\7NN-^0! M["&.M%&I-RO-36V0BB^,Q$#P=[7OWMX[SE9EK1&.D]F\@![-M;"A)WHSA]VLP=NPX=BO]#D?18U[W.]20_4B,2H\\UQ;^+FMZ4VB MN>&.G<";YD.L7B8Z^%Z0'1H>)AH-/=^)6@V!R[C#JX8[I$;U[7JC1+PEN D_ M&?[O=6 %MMA[79,_X>U0!)SA$!7Q=6S=OBD=N$X@G*!R-1T!L@WYUYM2("9! M3;)@#?O5U+"O_Z]286\M89L[K"."77;&AV*'3RW3?./PL@+8 ?/A_VP$$ M3@\ ,QZWCQU33#Z(Z>;6VN8BXVYKX[:&PC'AW^"MS?N?>]SVQ0)# M;>X#F@\_-SXKL2#'A$>+C-'\W!EP3_B?FY])"LI!?'JVR#B'",N%&FLM ]+, MP;NN.65^,+7%FU(/J&^'->JC@%U90VAR)N[8I3OD3ED^* , GM4C.C>MV["? M:?DCFT]WF.,Z@EY:DQTD6.$A)]!?EFD*A_@"_X2&9V,@,,N0)#\)+E%NM/SS M'M)*I;Y= 79B#JP4AA?63BX%E/9B$GA=2PR[_$P)FBCM$5'D#EY++ OG NDF M/%"XPI9;K!],SJ%;])@)0 ( M'RHT)G$[=BR)6&"I##:'@OMC3^PIWMN!-N%@X:OD%#C:C/$E(\^<0B&!&BT] M1RPP,O, <\,V9G&+?8D)>.!ZVNO%<9"&,6]4;=)#X;A#R[EOVOOQDIXW;^#P M?0(+&80JKM1X4(J$4.Z]KD%_^(G_O!Z%LG+(O;[E[+#Z+D-Q6_&M;T+*W-+> M:W_$G<6%\7_^U=BL[[ZN86^P-49[R1D?.M NBV"#IO52/)2F@"['MJA<\#[I M25T'R+Z5P!W1VM2?73<(W"$]N;/,8(!PU'\K)7IV70\0)GONV]RX84V8WW=M MR]QEZF4XCGS?B-_K.$04AKA U*O_:M#7$N _$IK"*6?@?6O! 7<9BIT*MZT^ M/#) 9 H/$-;=NSX[OFH?LLY5ZZK=>5WKSM[J1YNRTSZXOCR^.FYW6.OLD+7_ M/'C7.CMJLX/ST]/C3N?X_&PN'(OB_;VD1:X.)_ML#48CX\#-V*LYL:]?/64^&8I?#\:8;\]OSQE4MRB)D03>KO> M),^@4CETC3$:@.B2?38B)R9V9[Y-._M;'[Y>BQO#@.&6L3+U.4I[6Y4/:1,S M$NV(,N /8;QD!@_>-[;7U?PKUH]>! M:[H4(]<+V$KXM^!@40H_8.(66C*/7@MS=0<0M9<63ULI\71!7DM;^C3Y,H%<7 M',A&F>'(61?Z'RKAGIH0K2=%Z,;]YO??7H2N/Y8X2[-@6[&@C$9=BK[E8Z ] MP(A.6^UWG?9D_]OIS9*60MY MM,[7WVTM)*4T,P&3DAB5#<3(;@J+MQY2[K::;GP9!]H[*V MU6AN_Y/1O)E \Q6?'*NTA$&T-P_GWXSS+W?&R=K%V]YWX7S&I+ !ZY6UCCUC%<_? ?B/ER=I;H47P!1VB$V0X[,U-'$=>F0N>& >^P+^EV]:TE73W#-+ MY]15)C5T>CMGS!%"GM?EX;".9L\2Q9=GA9MS**G2XT/+GN[<)_&S47E VH$[ M'%H^EM7(56FA=K;$_Y[2VE R,$F9JTS?N6B-OVK??_(>'U]V6'LXLMVI\/YQ MNYP41.S,K<[;[%#0U,BJ>GY6'.W>/'*/AES?_JUTC^YIF:8G?%_].+$_0WZ1Z,C'Y@SQ4'L"OY]Z5>^?D(_+LW>'U]&3K_='6J^]2X)GI2GL'?-CU M++,_RT1-<%,W-DP61DDY.0I09@HSK_(P0\K]W+L $QP4^ QK_^WUR5_.NYL_ MKYL_UMC/AZFT=\I]GQN#L2^"P)^+Q\#,,F-D>::LS%2SM+Z1@C5/""5Y.4.! MZWEXOG!A]?9?UFBV3^7^U1ZMO;^:KMGFK^+F!)1@=C8;:SDVOT:P:1OS7CFH MJ^M'CR6I56 @Z<(#TK%&((7:$V&, Y!$[+P'ZDSX6O!H6>F3<'+4FN<2UX-< ME^\R1F#3Y*RX=;FJ.D]-/_'8F3)V1D'6W,%G>5/'<<___&NKV7BUZT,S6XP& MKB.80U9K&7T5>XS60;' /<&!54Q!*925-#.O*69&D=Z"IK/9=V-PNGGR;?H> M'/ E=8@^1VEOL_%JAJA;S8BR#JS(%8VL@ MC!M,%#,^ D-C!&9H($"33UA7V.X=8@I?(C[95N4#ZUDV" %F^2 1 N&8PBP6 M A>P.!S; 7>$._;M*?/!!?)[4^JJ>KA=F%EZ1C(SK69:#+N8.J\BG\Q3B'X [%-=^UG4*K:T_ M/"N +<2XR]A17JN?+_^Z^XUO-W?#SN_#[K+V[$[7=6W!'2KVUB5C+A@2F5N[ M,X6C_+&"V"@U7'[NH]+O(YI>4P?Y(B'\%K$\"+W,$P*$2 !T7-#(0IM,_!:&/ 8A\ M[M\*C*O3X:GK_FD].O=G87B2K!^#62P,%:!9OF^L\TJCJ;%^HN J8OSU>E6V M?.']%][_R;P?%N!>> (U+AYVHAI9-.4\4"OQ.#=^+3==4\72]@]1 ;, MAN5)R@( MV)H\-YO#S36S4ISI;OZ,,D@V[[(AA?9\#1DP['OCX5WKX3PVH=' M8O/HTWKG1PN(#$#_%#&Q)BKK*\;#Q(1J^^ABX@>4\1FN[7H[[%_-9J/=>(N% MRY%#)&, PA-F AU173M*PK"4'7'P>.YZ%JPGF">=EQW-S[Z4LI'TL"!H[:$% M0=\357]PB.8*KVN0L%*5OC%@ALU]/R_)-R]'M?6T5N5Q&21':#O38=>U5_S5 M!=>TMOVDUH35T,F-$J%4 A:]&UCP).;C&6N-NL%2 M'$T;S2X1Y8QS'G?;G^SIYL9!?=F$=WJ>TAXJ-4!A)W"-FS+[=[V*)_W9B'OL MEMOCV?GO.23T _$5IDP4C4OJGI&8O?[XSC^;\-Z[C261E9BDM'=ZV3E[8NA( MDT^HJF9&3R%@N)U+:.W9,M,<$ZTZ90:D0:'4#0DU0Y68J36'Y M#$@ K#D2>LG!+[W4=YKA3R1*U<(8CFN! CI\O)P;G?W0_ :C#[N-G M6^8 \T OZJG2S7=*@J5)Y[BG"X5B(4E!6#F1*V*L3!)T /)#V.#Y@/QP7/*# MQKZ@5K!,RK4RNG/.(M](WJB#FTYSV5,DWSL+IH9IBP4'X(57GKBU?.@(8HD[ M!D:MN4&WLV%KO/'/Y)[IRRRK.+LD] ME0MX:!>\_/+393\)[PCS+K3_.L:8"PPK%T F81:7,^^[T7>IT9&];DC'[6@OO)LH,[TG^$VE*X!Q <81P:Q/N9DS(X*QZ)3ZEO[8W8PC M)7ID)!TY^;Y(R8.JV[JPDR!^P7>MJ. .>*=X5/Y^MS/KA1.1H0V<>=.@"&MW M[S@00[91K3>C2MH9GD=4;0.=#@7X=\'8H\.[AY8',M;U?!35!P 9!\-1%EUZ M_BYKVTH"ZTUWL93*M9P @XKX)M.O6$"-+AP?;]R:LI;GH<#&YGY>^VI\\HCL M_<'(%)A-$-;>I0@ I2$26X[#BX4+SP6P^8ACS?2/*E*['[I? MC)QSAV7NEBB#?P$H8C&&RO"[\.DF0K X3'8PL$0O4SOL(7)/Y36G#)Q1CX\$ MO#>@^[%C5-D*VA18=]JL[RH[E/YJ[*Z68ZL$&ZFWQ0+9.& @P>@X./II)@ " M'(5@4%D:,0U8,![M<9E>N/JJ-M6J])&AE0/8,&"^4V"*>*6J+%:-1A0C>CUD MS5MPNS@QE8:PNAP[L32-V/#RCG")U=1,(/-L&^89(G]R-I0C*LM+0P\5Z>Z[ M8+HE1,-S)=AC!_TB1PE+H@_ J\[.V2TL)PEB(X\@*&!$WCS0$M?W'PG*1TDN M*QIYWQ/R1?ZF _.$+<*MC\#4MA]^U\QO'$FCFVB$%-'B8^00'C KD 0TXM,T M85&%I^.,N5TL&-P?@-'HC'TMTY2FKF8=LTW8]-DZXYM$QP8 M8/NN$ ZC2TAM(;T3603J@\YE>+<-O)0A\D-A2-RO*1D# P!6R2E"!H#N0IX5 M--%WTA<=#( ,^@/FCP$6O#R'9$4%=D.;$VMYE?*DT?%Y'O0@46 )W @ .?9T MYISZSM)XA)=86!$L\0O$51?0P='[ BC"8N!96^B#SC$\D1R&#T!'>(:V@RFJRB*=6"); !!0V )=GDSI83GF>2]#7N*;,5:Y5>^Q3-=$>TQ7UTH)$+W#1EPLOW',@> M[" U;R.]DPUV3J-HG G(, 3L'+L5/GG*J$[P,JV4'"]K2):DA<28*]2).7CH MM9-(AS4QNO6)B$5,A&=8RN''>=$;CTDXD!L6 @OZ>,52J$B+ E?%"Z*1: 6] M&5K-'0<4!Y !@1BI/@DY4/&!9U%,0KZDJVU70@G7N0ZQ!B1SAZ&$LCKT3AN> M!CIBW'!/%$%N(/MTOP!]9[Z,%72@3EJ#" 3A;*#4RX@7W7TQ&:**,1Y*4 MU+UDD7+'[5*_\NBD!*A!;Q@^5I-PVE>-='@/^2M%-5H[]#$9N!M[F&/D9H6>6Q@I&H[^. MK0"&0XF,RE@>J9&R!!4H-%'B!*8"Q6L,D((;F^7-]36FOETP SD&Y:R+!5\F MK:764X-IBL[19*:'> >0@%F4@#5LUY>'>Y03-WNF4,3*1:A4YI'M=F$T%1_N M4-2\6%"I3=745!= ]N7=:%+VP](9*"V%&:22!1;-U)I)\D-+N79:-&I91'1O M;(.!G1+QL&C7 ,K /N_'CF!;T@!BRE -([? MKSLQ14E\X(*I-T-[XO)04X;V @)591U\E*"FT%(,3:ZTV9;K1\C4,SC\Z!B@ MTTS>A&Z'X8/( ,/-0IL<7 9C;)-1']G19)6"6HSV2B%' 2EW.S;U 14 ML0 I9I&Q.]L+>C ?W^. X)_D_,QR0@BOP%6P.4I&Y4\=VYMYX,XG%&F@ )62 M"_!L=9*UEPJ@@MP =!4+[\9TU/FT>E@MXQX\*+[U$BA,A=02;BPCJRD.K%&8 M0N*;)=!-+KC<%FBF A9I\G[0AI3G!N<:.<$Y @1D%("5BLX=>E4)IO()E36! MLDYRJA)(+P;UXYN @/N()3%]M0F6#J;("?'FMB 8/6X;TQ $#7<@-A#!Q847&;O!"<@+__#AZ/=0P4BV0D 89."UZA=+->3.I8'9:4HDD/I M@] "6N,^;(_T9J%G-"0M&GI*!CH56)]@1_%ZV37&D-ZSRO8I;TDHHR >(:FL M,4H,6/[PP/]7[4[K\CQ, "@FE _C*WT7&/LRQB7Q"_!&',U?GH/ MM7@ ,,?C2(UH@%V@*B; +SNR^<3M#,%\_X#%K6QD&Z@0PW $#+1=5BXV;#MY MUK"2CG 0^[^CV:3MW $,@6M3\*A!B@4'ZVTB\G M,Q'+M9A(-7OD^U3?8CD-T(^.BGU^0=1&PS?IOE#NT(IM9 M@P7%:^Q1D8]A ,)OHV2Q/G;?!89DID"?A'(6R;3!/). ,,:'6(U55CX-KA<( M1L;$?4**RDP2C(E8_3)SJFO!-5PEO,?8N9H%2!R;E,",;-I/97-).2"3!B[] MK+(6=%-MN46QC9@=C5<2S\.C>J -4Y+4.4^4N ;%87G(7N MB0H#=A0(I&1,A9(Q87J(,K!D/2:D:X3Z"&^Q[HWS532H)F>3 ;D87_X/";>J MP&Y^O'5.@/6>9*YN%\RFP3@T6RR@:MC*+H\$Y]!=ES$(( MG"CX&Y-:78Q\$9MZ*2F@=68K+B!=<1J5(@314"!?Y%@8\ ,_9(Q1P;YU MB[!X5/W@ZE@H)^>TAD/P*&%&>QI'1"AM04/1/?KE.->CU0^"S:_*6;#$!_-% M4@%$(3W#!?9%L\'*#^DA^8U@#&ZCG ?Q07"EV7:"7_DXM$21)0I1H)NCT C_U8QDW1*(K1IY5UDP^-X-$.$-*S&N5"3P0AN6*"@,J()"0> [( M\)7]5=:H;H!8\3>[FU$$O)O5GM'R[V(OOL>^0>>S2QI^?9Y\@]UE)V,M:; MEG,,DFP9GA0&,L==D;EP66Z74K-:,1_L4YZV'&A2AH@EY*\ I(7*O<&2D:94 M$:(J:Y 5*/DJ.#7HLY7L.;:EC($J%\^5XB 43+'8BVMT1-\E?KYS\2((#L[5 M"!C=\N-HG,P9(,J%# "' CI;B89;QV_==(8,X[XR>!^[''2&U(HY&J_X=GH4 MIA!5H&CGB5Z!7T+%N*H;P3P_,NJFE/!E;7"H .JHTP13NC*BF\\Y[6 M1U_/D+%]1]YTW:DT%!B10QA?N2"Y)SH''7^WBHK-,57:H%J(QBMY(,G7/O2% M>3;A"8N2D9X 6PE#M]ES'PGJF$D4J5J+(9^B(/=038 _5$9]AE5 RI#$H]7D MEH7C35.1>$,=#!03K&X2OG;K/^-!X'J.F$;EV#V!#;Z,S3Z9< *VH&^.AD3 M*)FG5"JA $LC21=B*@=M",PGJ/.-'I*I(82<"QQ!*E\:!Z%-IE'>W.R8W)L9 MZ;%G*[>NJ!S!PG(V0&YT&I3\3N*?Z ! OI2A^D"B(K!%,3:AA]-DP$V+15!J M6]UC\)!L9K$P:[^8!!R+]1PT^F4I()Z?GHQF%&5'^G 1-X9Z85\5QF+=6Q)#/A8NM"6 ME$.1_%7FER53UIY \IIS""EWUC*J/A7[E2R1""/2QQ+(6D>](M4*)F(_CNGS MS "B^G!]J((:]UZJ=!M%&Q;/^$8KR&P\-M6 9Z)TD_*4C5,6 MS_XG>F+[8C .](?#E'!V9 MUSNS'#S7MTHG>%6.B @[#FJ1X11&*M#2N^6VD+,X6-$6Q[(R> P/I^BE+GI& MR@!R @KTZ)2GYR(LN":L'B>S+(I#F&&PW=^-@U56/&,8:(J]RT08R7+\L5Q, M%$B1.IFB0F66.7*3 I8TPDSY/&S&/:V>S%S)YS M:&K?L[B#EWATC,%X&CBR4EX:>>J\4&-;6?$Z)'CH54&A#A$E2@2*A33EQ9A)0_)7^_WU28L"\%C[B =QHM-% MB2,Y,A@?'V1J;&<)/'4.IE6E/'?7#J4\NJS$ J]T//'4LYA!4!7AAF/S. MG(C!_A@0H@//BN\P%Z>A3OE"!GH8\7TZ"H&(D3_ ^0@H_F@,7-<.W9!K66>( M"3G\:+-P'']JWW+'XL^6LQ8/;ZN-1>X[/2>6:F.MF_\L[QD-&5NS MGU]N%UTP))TQBD]=K(O-CW^)"="(XZ"P3HDY%X3Y%&YI%'"[#G@[X&M K; MXK/V*9\H6O$%^9'BU4D"-)=.$ZC;HHGFTT5F/EE':X<.5S3,0MX6UO&$[I9V MN?]S][=0])+NT2_#+A;TV[!?Q'#JI'C,8M'U1@?1O:+*5I.'BL/KGS 7U>][ MHJ\*F=?6Y'G!R\XU7FZ*M[>IZYCC>E5Y:X>L)@W0@B9IJ5TJ&@@^5!<5% OJ MD):?O6@+8WBA:RGO=5E/Y+.HUE("*N8?LDI=]1K>A?6LCU8!_\BMCBG@4N"I M@, *9$7V^?(B &:*B/7CX[KQ[Y?#B>']2MG MKJS85@;(05BDR(XPL2EC%1G^O_^2@0?=P%0%)8UOD@RL75;Q:'#+K#H51D;D M*W6TS![[C_E1T4=R+'_1)T?QVWD+?J!1#;Y1_QG?K,RGBX=^5_/GP+@0<<[X M3.82^_!CUW7(;RT3O*X@8"L' VYYJ]__V<6E@?D#&!IESCL,*GDB#Z*GBL<6 M&/L.2$K^[1?B[X3?R;PK0G/+_PYX^^#AYV4==@I:4&!Y#E:A_4(4IN#)1^'C M?37S;V8>3I0[[[H>08,7=WKW-\=-:ZNKYL=Z1> M?:J?#H@3_3AKN0QI,27&,,/ORH//O552?I6B,'I#D7Z"JQ,^ZC/ M ^"A<7FF$+UQ58NH/&*9/I,-,/NB?7UU?- I2S"/ MSPZJ#[%D4V/OLF6Q%VW7!GTH5H;WG'(! [#=7^Z,Q>DE.W13=L>OP#DFE^38&:JP'X:KST^"_R<$9=%>5BP M@3,^0M'&CW8-?M&W=3=VU0>2_!UV@N=SGHPU__.^>_N(F*YU77.*Y% ;!$-[ M+XG[C@#$G/$AH'UB3G;9\2']\KF^M?^93IOX5/1#ZZ1^XOWD[1>S_>'N2^OT MLKO=KTT.-T].SL9?3UIK[SJ>]7;_QKH=?/ISU.TWCO_;'/YW>E6K>^Y@<+-_ M_.I+<^.C^ZT]"/CFY7'WY-2O]0=O?S<_N.+C^EW]KV^7?VP?;Z^-V[>M;Y-7 MX^:7T>^36L\]O*X=GXKA)SZQS=JKC680V/V;XR/SR]&GK2\'5^_/1\[9IU?M M/^\:OY].SQK-OO'[U]_=]MW^Y2;G9U?>V[7>X6#T=N/FZ[FW.3H\GS;^^-@9 M'E].;\ZV/DZO;]K[3>_WF]I@<&P$G?:G;YL'?N?H*Q_63C\U8,BCKY/3D=/\ M^&[;K+7V&_;@_6'KS1N)DO\'4$L! A0#% @ CDF5V5]XN(I P X L M !$ ( ! &UR'-D4$L! A0#% M @ CDF5RZU(T7]"@ @(8 !4 ( !6 , &URD1+"?5 < --7 5 M " 8@. !M